Usana Health Sciences, Inc., a Utah-based nutritional, skincare and dietary products manufacturer, indicates in its recently filed 8-K that it has substantially completed an internal investigation into whether the expense reimbursement policy and other practices at its Chinese affiliate, BabyCare Ltd., were compliant with the Foreign Corrupt Practices Act. The company reports that it is cooperating with the DOJ and the SEC in their investigations of the matter.
February 5, 2019
DOJ and SEC investigating nutritional supplement maker for possible FCPA violations
Related by Topic
New Post
Texas executive agrees to forfeit more than $1 million after pleading guilty to FCPA violation involving a Mexican official
April 20, 2026
News Alert
New Post
Federal judge in Texas overturns conviction of defendant charged with FCPA violations
April 17, 2026
News Alert
DOJ closes its FCPA investigation into Dr. Reddy’s
April 6, 2026
News Alert